127 results about "Cholestasis" patented technology

The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.

A levo-potassium magnesium aspartate freeze-dried powder injection consists of levo-potassium aspartate, levo-magnesium aspartate, freeze-dried power supporting agent and pH regulator. it is a kind of electrolyte extender, contains no crystal water, and has pH value of 5-11.5, large dosage, physical stability not affected by temperature and no pollution. It has wide application range, and is suitable for intravenously guttae to treat arrhythmia caused by various causes, chronic alcoholism fremitus, myocardiopathy as diabetes complication, etc. and application in heart operation. It is also suitable for acute and chronic hepatitis, intrahepatic cholestasis, and diseases of respiratory system, nerve system and metabolic system.

Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt.

The present invention relates compounds useful and their use for treating cholestatic and fibrotic diseases.

A leveo-potassium magnesium aspartate infusion injection consists of levo-potassium aspartate, levo-magnesium asparatate, osmotic pressure regulator and pH regulator. It is a kind of electrolyte extender for infusion, and has pH value of 5-11.5, high concentration, large dosage, high stability and no pollution. it has wide application range, and is suitable for intravenously guttae to treat arrhythmia caused by various causes, chronic alcoholism fremitus, myocardiopathy as diabetes complication, etc. and applicaltion in heart operation. It is also suitable for acute and chronic hepatitis, intrahepatic cholestasis, and disease of respiratory system, nerve system and metabolic system.

The invention relates to applications of serum taurochenodeoxycholic acid and chenodeocycholic acid as diagnostic markers in the preparation of medical instruments for diagnosing biliary atresia of newborns. The diagnostic markers of the medical instruments are content ratio of the taurochenodeoxycholic acid and the chenodeocycholic axid in serum. The invention also provides the application of chenodeocycholic acid. The application of diagnostic markers in biliary atresia of the newborns has the advantages that the application of the taurochenodeoxycholic acid and the chenodeocycholic acid as diagnostic markers of biliary atresia is proposed for the firstly time, so that the biliary atresia can be distinguished from other cholestasis diseases of newborns, the best operation time of children can be strived for, and therefore, the operation effect can be improved.

The invention discloses gardenia polysaccharide and an extraction method thereof. The gardenia polysaccharide is prepared from the following raw materials (by mass): 41 to 56 percent of total sugar, 34 to 45 percent of uronic acid and 7 to 10 percent of protein. The preparation method of the gardenia polysaccharide comprises the following steps: crushing a gardenia medicinal material, degreasing,adding water, extracting, precipitating with ethanol, repeatedly freeze-thawing to remove protein, dialyzing, and freeze-drying. The gardenia polysaccharide prepared by the method can improve cholestatic liver injury induced by alpha-naphthalene isothiocyanate (ANIT) and 3, 5-diethoxycarbonyl-1, 4-dihydro-2, 4, 6-trimethylpyridine (DDC), and reduce fibrosis induced by carbon tetrachloride (CCL4).And the liver protection effect of the gardenia polysaccharide is not reported in literatures, which indicates that the gardenia polysaccharide has obvious application prospects in the preparation ofliver protection drugs, especially in the preparation of anti-cholestatic liver injury and anti-hepatic fibrosis drugs.

The present invention relates to a compound medicine formed from diammonium glycyrrhizinate and one or several kinds of halfcystine, glycine, methionine and vitamin B1. Its therapeutic action is extensive, and side effect is low. Said compound medicine can be used for curing the liver diseases of acuter, chronic and virus hepatitises, cirrhosis and fatty liver, etc. and can be used for improving function of liver and cholestasis in the liver. Besides, it also can be used for auxiliary therapy of alcoholism and barbitones and sulfonamides drug poisoning.

Disclosed are compositions and methods for treating cardiovascular disease and reducing the adverse effects induced by the administration of statins. In particular, disclosed is the use of antisense compounds to augment the expression of mirR-33 and associated genetic elements. In particular methods of the treatment of cardiovascular disease and the modulation of miR-33 levels is disclosed as well as treatment of the secondary effects including cholestasis, induced by the administration of statins is disclosed. Also disclosed is the treatment of Benign Recurrent Intrahepatic Cholestasis and reverse cholesterol transport. The disclosed methods and compositions may be practiced separately or co-administered with satins to reduce or treat statin induced secondary effects.

The present invention relates to compounds of formula (I)

wherein wherein R¹, R², R³, R⁴, R⁵, R⁶ and n are as described herein. The compounds of the present invention can be used as medicaments for the treatment and/or prevention of diseases which are modulated by PPARα and/or PPARγ agonists. Examples of such diseases are diabetes, particularly non-insulin dependent diabetes mellitus, elevated blood pressure, increased lipid and cholesterol levels, atherosclerotic diseases, metabolic syndrome, endothelial dysfunction, procoagulant state, dyslipidemia, polycystic ovary syndrome, inflammatory diseases (such as e.g. crown disease, inflammatory bowel disease, collitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as e.g. Alzheimer's disease or impaired/improvable cognitive function) and proliferative diseases.

The invention discloses a traditional Chinese medicine composition and a preparation method and the application thereof. The traditional Chinese medicine composition is prepared from eucommia bark, radix scutellariae (preparation), herba artemisiae capillaries, capejasmine (stir-bake), rhubarb, herba hyperici japonica, dittany bark, Tuckahoe, salvia miltiorrhiza and radix curcumae according to certain proportioning by weight and can be prepared to any common peroral dosage type. The traditional Chinese medicine composition has the action of kidney tonify, miscarriage prevention, petechia passing, cholagogic effect, invigorating spleen and eliminating dampness and is safe and effective to treat pregnancy intrahepatic cholestasis, ABO blood group incompatibility, icterus neonatorum, and the like.

The invention discloses an application of deoxyschizandrin in preparation of drug for treating cholestasis liver injury. Deoxyschizandrin has molecular formula of C24H32O6 and molecular weight of 416.51, and has the structural formula shown in the description. Mouse liver injury induced by application of excessive lithocholic acid (LCA) is taken as a model. After application of deoxyschizandrin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in serum are significantly lowered, while necrosis degree of liver cells is significantly improved. The results indicate that deoxyschizandrin has treatment effect for liver injury induced by LCA, and can be used for treating cholestasis liver injury clinically.

The invention discloses pharmaceutical composition for post-operative nursing for cholangitis and a preparation method of the pharmaceutical composition. The pharmaceutical composition for post-operative nursing for the cholangitis comprises components in parts by weight as follows: 12-30 parts of p-coumaric acid, 15-32 parts of naringin, 10-28 parts of cordacin, 10-25 parts of a water shield extract, 15-26 parts of mangiferin, 8-18 parts of red halloysite nano-powder, 12-24 parts of limonene, 16-28 parts of eucalyptol, 14-20 parts of chlorogenic acid, 6-12 parts of levamisole hydrochloride, 40-80 parts of a magnesium sulfate solution, 50-100 parts of corn steep liquor, 8-16 parts of potassium sorbate and 13-25 parts of mixed amino acid. Effective components of Chinese herbal medicines are added on the basis of Western medicines, the pharmaceutical composition has effects of resisting bacteria, diminishing inflammations, inhibiting intestinal infection and preventing cholestasis, effectively regulates functions of the liver, the gall bladder and intestines of a patient and improves various anomaly indexes of the body, so that relapse of the cholangitis is prevented, and post-operative body recovery of the patient can be accelerated. The pharmaceutical composition is simple in preparation process and convenient to use and has the great clinical significance.

The invention discloses a construction method of a pancreatic duct epithelial cell and pancreatic acinar cell co-culture system for simulating in vivo microenvironment, and belongs to the technical field of cell biology. The method comprises the steps of inoculating an upper layer of a Transwell dual-layer culturing chamber with original generation pancreatic acinar cells, inoculating a lower layer of the Transwell dual-layer culturing chamber with human pancreatic duct epithelial cells, performing co-culturing, adding sodium taurocholate in the pancreatic duct epithelial cells at the lower layer of the Transwell dual-layer culturing chamber, and observing the vitality, the shape and the apoptosis of the upper layer pancreatic acinar cells. Damage of the pancreatic duct epithelial cells and the pancreatic acinar cells are combined, a non-contact type co-culture manner is adopted for building the pancreatic duct epithelial cell and pancreatic acinar cell co-culture system. In the co-culture system, the two cells can exchange exocytosis secretion substances through Transwell transmembrane. The system can well simulate the pancreatitis induced by cholestasis, and the invention provides an in vitro cell model which can really reflect pancreatitis induced by cholestasis.

The invention discloses application of ACOX1 as a detection target spot in preparation of an ICP (intrahepatic cholestasis of pregnancy)-assisted diagnostic kit, and particularly relates to application of the ACOX1 as a detection target spot in preparation of an auxiliary diagnostic kit for intrahepatic cholestasis during pregnancy. By separating and studying ICP cases of primiparous and singletonpregnancies and comparing the ACOX1 in serum/plasma of healthy pregnant women matched with the ages of the ICP cases, the inventor finds that the ACOX1 is a highly-specificity and high-sensitivity lipid metabolism molecule which is highly correlated with ICP incidence, thereby providing laboratory support for screening and diagnostic treatment of ICP.